-$0.13 Earnings Per Share Expected for Sangamo Therapeutics Inc (SGMO) This Quarter

Wall Street analysts forecast that Sangamo Therapeutics Inc (NASDAQ:SGMO) will announce earnings per share of ($0.13) for the current quarter, according to Zacks. Two analysts have provided estimates for Sangamo Therapeutics’ earnings. The highest EPS estimate is $0.07 and the lowest is ($0.24). Sangamo Therapeutics posted earnings per share of ($0.15) in the same quarter last year, which would suggest a positive year-over-year growth rate of 13.3%. The firm is expected to announce its next earnings results on Thursday, November 8th.

On average, analysts expect that Sangamo Therapeutics will report full-year earnings of ($0.69) per share for the current financial year, with EPS estimates ranging from ($0.89) to ($0.42). For the next year, analysts anticipate that the business will report earnings of ($0.87) per share, with EPS estimates ranging from ($1.06) to ($0.44). Zacks’ EPS calculations are a mean average based on a survey of sell-side research firms that follow Sangamo Therapeutics.

Sangamo Therapeutics (NASDAQ:SGMO) last issued its quarterly earnings results on Wednesday, August 8th. The biopharmaceutical company reported ($0.17) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.15) by ($0.02). Sangamo Therapeutics had a negative net margin of 105.65% and a negative return on equity of 26.36%. The business had revenue of $21.42 million during the quarter, compared to analyst estimates of $21.43 million. During the same period in the prior year, the business posted ($0.17) earnings per share. The company’s revenue for the quarter was up 159.6% compared to the same quarter last year.

SGMO has been the topic of a number of recent research reports. Bank of America initiated coverage on Sangamo Therapeutics in a research report on Wednesday, June 20th. They set a “buy” rating and a $24.00 target price on the stock. Cowen reissued a “buy” rating on shares of Sangamo Therapeutics in a research report on Monday, July 23rd. BidaskClub downgraded Sangamo Therapeutics from a “hold” rating to a “sell” rating in a research report on Thursday, July 26th. Zacks Investment Research downgraded Sangamo Therapeutics from a “hold” rating to a “strong sell” rating in a research report on Tuesday, July 17th. Finally, Wedbush reissued a “hold” rating and set a $9.00 target price on shares of Sangamo Therapeutics in a research report on Tuesday, July 24th. Three research analysts have rated the stock with a hold rating and seven have given a buy rating to the company’s stock. The company currently has a consensus rating of “Buy” and a consensus target price of $22.29.

In other Sangamo Therapeutics news, CFO Kathy Yi sold 5,000 shares of Sangamo Therapeutics stock in a transaction that occurred on Friday, June 15th. The stock was sold at an average price of $15.67, for a total transaction of $78,350.00. Following the sale, the chief financial officer now directly owns 12,250 shares of the company’s stock, valued at $191,957.50. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Insiders have sold 30,000 shares of company stock worth $458,750 over the last ninety days. Company insiders own 1.20% of the company’s stock.

Several large investors have recently bought and sold shares of SGMO. Riverhead Capital Management LLC raised its stake in shares of Sangamo Therapeutics by 218.0% in the second quarter. Riverhead Capital Management LLC now owns 8,267 shares of the biopharmaceutical company’s stock valued at $117,000 after acquiring an additional 5,667 shares during the last quarter. Mount Yale Investment Advisors LLC raised its stake in shares of Sangamo Therapeutics by 2,202.8% in the second quarter. Mount Yale Investment Advisors LLC now owns 8,359 shares of the biopharmaceutical company’s stock valued at $119,000 after acquiring an additional 7,996 shares during the last quarter. NumerixS Investment Technologies Inc bought a new position in shares of Sangamo Therapeutics in the second quarter valued at approximately $125,000. Tyers Asset Management LLC raised its stake in shares of Sangamo Therapeutics by 301.3% in the second quarter. Tyers Asset Management LLC now owns 9,632 shares of the biopharmaceutical company’s stock valued at $137,000 after acquiring an additional 7,232 shares during the last quarter. Finally, First Mercantile Trust Co. raised its stake in shares of Sangamo Therapeutics by 93.7% in the first quarter. First Mercantile Trust Co. now owns 7,666 shares of the biopharmaceutical company’s stock valued at $146,000 after acquiring an additional 3,708 shares during the last quarter. Institutional investors own 63.95% of the company’s stock.

SGMO stock traded up $0.50 during trading on Wednesday, reaching $15.80. 57,800 shares of the stock were exchanged, compared to its average volume of 2,034,642. Sangamo Therapeutics has a twelve month low of $10.40 and a twelve month high of $27.50. The company has a market cap of $1.56 billion, a PE ratio of -21.86 and a beta of 2.74. The company has a quick ratio of 7.24, a current ratio of 7.24 and a debt-to-equity ratio of 0.07.

Sangamo Therapeutics Company Profile

Sangamo Therapeutics, Inc focuses on translating ground-breaking science into genomic therapies that transform patients' lives using platform technologies in genome editing, gene therapy, gene regulation, and cell therapy. The company's zinc finger DNA-binding protein (ZFP) technology enables specific genome editing and gene regulation.

Further Reading: Diversification

Get a free copy of the Zacks research report on Sangamo Therapeutics (SGMO)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Sangamo Therapeutics (NASDAQ:SGMO)

Receive News & Ratings for Sangamo Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sangamo Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply